ClinicalTrials.gg
CompletedNCT02431754Updated Jul 2, 2017Results posted

A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).

A Phase 4 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 9 sites in Japan. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
16th of 26
171 · median 258
Started
2015
with 2 others
Phase 4
6 of 26
1 open now
Registered
19th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 16th largest by enrollment, is one of 3 that started in 2015, is one of 6 in phase 4, and was the 19th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker. This study has two treatment periods. Participants will receive tadalafil or placebo in each treatment period.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with benign prostatic hyperplasia (BPH; also referred to as BPH-LUTS), based on the disease diagnostic criteria, at study entry.
  • Have been treated with a stable dose of an alpha1 blocker (tamsulosin 0.2 mg once daily or silodosin 4 mg twice daily) for at least 8 weeks prior to screening, and continue the same alpha1 blocker at the same dose for the entire duration of the study.
  • Are Japanese men.
  • Have prostate volume ≥20 milliliters (mL) estimated by transabdominal or transrectal ultrasound at screening.
  • Have BPH-LUTS with a Total International Prostate Symptom Score (IPSS) of ≥12 at screening and baseline.
  • Have moderate LUTS with urinary peak flow rate (Qmax) ≥4 to ≤15 mL/second at baseline, while meeting both of the following criteria:

    • Prevoid total bladder volume ≥150 to ≤550 mL as assessed by ultrasound
    • Minimum voided volume ≥125 mL
  • Demonstrate ≥80% compliance with alpha1 blocker treatment* during the screening period, documented at baseline

    • *Tamsulosin: (Number of doses taken / Number of days to be treated) × 100
    • Silodosin: (Number of doses taken / Number of days to be treated) × 50

Exclusion criteria

Exclusion Criteria:

  • Prostate-specific antigen (PSA) >10.0 nanograms (ng)/mL at screening.
  • PSA ≥4.0 to ≤10.0 ng/mL at screening if prostate has not been ruled out to the satisfaction of a urologist.
  • Bladder post-void residual (PVR) ≥150 mL by ultrasound determination at screening.
  • History of any of the following pelvic conditions:

    • Pelvic surgery or any other pelvic procedure, including radical prostatectomy, pelvic surgery for removal of malignancy, or bowel resection
    • Pelvic radiotherapy
    • Any pelvic surgical procedure on the urinary tract, including minimally invasive BPH-LUTS therapies and penile implant surgery
    • Lower urinary tract malignancy or trauma
  • Lower urinary tract instrumentation (including prostate ) within 30 days of screening.
  • History of urinary retention or lower urinary tract (bladder) stones within 6 months of screening.
  • History of urethral obstruction due to stricture, valves, sclerosis, or tumor at screening.
  • History of any of the following treatments within the indicated duration:

    • Antiandrogens within 11 months before screening
    • Dutasteride within 5 months before screening
    • Finasteride within 2 months before screening
    • Any erectile dysfunction treatment previously or currently
    • Any overactive bladder treatment within 4 weeks before screening
  • Have a diagnosis or history of prostate cancer at screening.
  • Current or history of malignancy at screening (except for treatment-free and relapse-free for ≥3 years at screening).
  • Clinical evidence or history of any of the following bladder conditions:

    • Underactive Bladder
    • Detrusor-sphincter dyssynergia (contraction of the detrusor without sphincter relaxation)
    • Interstitial cystitis
  • Clinical evidence of any of the following urinary tract conditions:

    • Active urogenital infection
    • microscopic hematuria as determined by a urologist
  • History of significant renal insufficiency meeting either of the following:

    • Receiving renal dialysis
    • (CLcr) \<30 mL/minute
  • Clinical evidence of severe hepatic impairment or (AST) or Alanine Transaminase (ALT) >3 times the .
  • History of any of the following cardiac conditions:

    • Current or history of angina requiring treatment with nitrates or nitric oxide donors
    • Current or history of unstable angina
    • Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention (e.g., coronary angioplasty)
  • History of any of the following coronary conditions within 90 days of screening:

    • Myocardial infarction
    • Coronary artery bypass graft surgery
    • Percutaneous coronary intervention (for example, angioplasty or stent placement)
  • Any evidence or history of heart failure ( [NYHA] ≥ Class III).
  • Currently receiving alpha1 blocker therapy for the treatment of hypertension.
  • Current or history of any of the following symptoms:

    • Symptoms associated with orthostasis (e.g., recurrent episodes of dizziness, lightheadedness, loss of consciousness, syncope)
    • Causeless fall within 1 year of screening
  • Blood pressure-related findings of any of the following at screening:

    • Systolic blood pressure >160 or \<90 millimeters of mercury (mm Hg)
    • Diastolic blood pressure >100 or \<50 mm Hg
    • Malignant hypertension
    • Uncontrolled arrhythmia
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Tadalafil

    5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods. 0.2 mg tamulosin once daily or 4 mg silodosin twice daily. Participants will remain on stable dose of alpha1 blocker through both treatment periods.

    Drug: Tadalafil · Drug: Alpha1 Blocker

  • Placebo comparator
    Placebo

    Placebo administered once daily orally for 8 weeks in one of two treatment periods. 0.2 mg tamulosin once daily or 4 mg silodosin twice daily. Participants will remain on stable dose of alpha1 blocker through both treatment periods.

    Drug: Placebo · Drug: Alpha1 Blocker

Interventions

  • Administered orally

    Also known as: LY450190

  • DrugPlacebo

    Administered orally

  • DrugAlpha1 Blocker

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Preferring Combination Therapy Over Alpha Blocker Alone on the Treatment Preference Questionnaire (TPQ)

    TPQ was used to investigate participant's preference between alpha1 blocker monotherapy and combination therapy with alpha1 blocker plus tadalafil. At the end of Treatment Period 2 (or discontinuation), participants were asked to choose a preferred treatment between the two treatments given in Treatment Period 1 and Treatment Period 2.

    Time frame: Week 20

Secondary outcomes

  1. Change From Baseline on the International Prostate Symptom Score (IPSS) Total Score

    IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: Baseline, Week 8

  2. Change From Baseline on the IPSS Storage (Irritative) Subscore

    IPSS Storage (Irritative) subscore was the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore ranging from 0 to 15. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: Baseline,Week 8

  3. Change From Baseline on the IPSS Voiding (Obstructive) Subscore

    IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score ranging from 0 to 20. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: Baseline, Week 8

  4. Change From Baseline on the IPSS Quality of Life Score (IPSS QoL )

    IPSS QoL assess participant response to the following question: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?". Response options are Delighted (0), Pleased (1); Mostly satisfied (2); mixed about equally satisfied and dissatisfied (3); Mostly dissatisfied (4); Unhappy (5); Terrible (6), with a total ranging from 0 to 6 with higher numerical score representing worse Quality of Life from BPH symptom.

    Time frame: Baseline, Week 8

  5. Percentage of Participants With Global Impression of Improvement (PGI-I)

    The PGI I is a participant rated instrument that measures the improvement or worsening of the subject's symptoms based on a 7 point scale. A score of "1" indicates that the subject feels his symptoms are "very much better." A score of "4" indicates that the subjects feels "no change" in his symptoms and a score of "7" indicates that the subject feels his symptoms are "very much worse." The percentage of participants who reported a PGI-I score of 1 to 3 are presented in the table below.

    Time frame: Week 8

  6. Percentage of Participants With PGI-I (Drug Attributes Questionnaire) on 8 Symptoms for BPH-Lower Urinary Tract Symptoms Improvement

    PGI-I (Drug Attributes Questionnaire \[DRAQ\]) on 8 Symptoms for BPH-Lower Urinary Tract Symptoms.The DRAQ includes the following urinary symptoms: 1. Difficulty to void; 2. Frequent nighttime voiding; 3. Feeling of incomplete emptying; 4. Frequent daytime voiding; 5. Urinary urgency; 6. Taking a long time to urinate; 7. Need abdominal pressure to void; 8. Dribbling, leakage, and/or accidents. Each urinary symptom in the DRAQ will be evaluated by a participant using the PGI-I (discrete variables with seven categories) at the end of each treatment period, compared with how the symptom was before the participant's began taking medication in this study. The percentage of participants who reported a PGI-I (Drug Attributes Questionnaire) score of 1 to 3 are presented in the table below.

    Time frame: Week 8

07

Results

Posted Mar 1, 2017

Participant flow

Period 1 (8 Weeks)
Participant flow — Period 1 (8 Weeks)
MilestoneTadalafil/PlaceboPlacebo/Tadalafil
Started8586
Received at least one dose of study drug8586
Completed7982
Not completed64
Wash-out Period (4 Weeks)
Participant flow — Wash-out Period (4 Weeks)
MilestoneTadalafil/PlaceboPlacebo/Tadalafil
Started7982
Completed7582
Not completed40
Period 2 (8 Weeks)
Participant flow — Period 2 (8 Weeks)
MilestoneTadalafil/PlaceboPlacebo/Tadalafil
Started7582
Completed7478
Not completed14

Outcome measures

PrimaryPercentage of Participants Preferring Combination Therapy Over Alpha Blocker Alone on the Treatment Preference Questionnaire (TPQ)

TPQ was used to investigate participant's preference between alpha1 blocker monotherapy and combination therapy with alpha1 blocker plus tadalafil. At the end of Treatment Period 2 (or discontinuation), participants were asked to choose a preferred treatment between the two treatments given in Treatment Period 1 and Treatment Period 2.

Time frame:
Week 20
Reported as:
Number · percentage of participants
Percentage of Participants Preferring Combination Therapy Over Alpha Blocker Alone on the Treatment Preference Questionnaire (TPQ)
percentage of participantsTadalafil/PlaceboPlacebo/Tadalafil
Prefer therapy tadalafil + a1 blocker44.068.3
Prefer therapy placebo + a1 blocker56.031.7
Statistical analysis
  • Tadalafil/Placebo vs Placebo/Tadalafil · Normal approximation (Z-test) · p = 0.0937
SecondaryChange From Baseline on the International Prostate Symptom Score (IPSS) Total Score

IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline on the International Prostate Symptom Score (IPSS) Total Score
units on a scaleTadalafilPlacebo
Change From Baseline on the International Prostate Symptom Score (IPSS) Total Score-2.5 ± 5.1-1.8 ± 4.2
Statistical analysis
  • Tadalafil vs Placebo · Mixed Models Analysis · p = 0.1485 · Mean difference (final values): -0.7 · 95% CI -1.69 to 0.26
SecondaryChange From Baseline on the IPSS Storage (Irritative) Subscore

IPSS Storage (Irritative) subscore was the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore ranging from 0 to 15. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
Baseline,Week 8
Reported as:
Mean · units on a scale
Change From Baseline on the IPSS Storage (Irritative) Subscore
units on a scaleTadalafilPlacebo
Change From Baseline on the IPSS Storage (Irritative) Subscore-0.6 ± 2.1-0.5 ± 1.9
SecondaryChange From Baseline on the IPSS Voiding (Obstructive) Subscore

IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score ranging from 0 to 20. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline on the IPSS Voiding (Obstructive) Subscore
units on a scaleTadalafilPlacebo
Change From Baseline on the IPSS Voiding (Obstructive) Subscore-2.0 ± 3.6-1.3 ± 3.0
SecondaryChange From Baseline on the IPSS Quality of Life Score (IPSS QoL )

IPSS QoL assess participant response to the following question: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?". Response options are Delighted (0), Pleased (1); Mostly satisfied (2); mixed about equally satisfied and dissatisfied (3); Mostly dissatisfied (4); Unhappy (5); Terrible (6), with a total ranging from 0 to 6 with higher numerical score representing worse Quality of Life from BPH symptom.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline on the IPSS Quality of Life Score (IPSS QoL )
units on a scaleTadalafilPlacebo
Change From Baseline on the IPSS Quality of Life Score (IPSS QoL )-0.4 ± 1.1-0.4 ± 0.9
SecondaryPercentage of Participants With Global Impression of Improvement (PGI-I)

The PGI I is a participant rated instrument that measures the improvement or worsening of the subject's symptoms based on a 7 point scale. A score of "1" indicates that the subject feels his symptoms are "very much better." A score of "4" indicates that the subjects feels "no change" in his symptoms and a score of "7" indicates that the subject feels his symptoms are "very much worse." The percentage of participants who reported a PGI-I score of 1 to 3 are presented in the table below.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Global Impression of Improvement (PGI-I)
percentage of participantsTadalafilPlacebo
Percentage of Participants With Global Impression of Improvement (PGI-I)61.153.4
SecondaryPercentage of Participants With PGI-I (Drug Attributes Questionnaire) on 8 Symptoms for BPH-Lower Urinary Tract Symptoms Improvement

PGI-I (Drug Attributes Questionnaire \[DRAQ\]) on 8 Symptoms for BPH-Lower Urinary Tract Symptoms.The DRAQ includes the following urinary symptoms: 1. Difficulty to void; 2. Frequent nighttime voiding; 3. Feeling of incomplete emptying; 4. Frequent daytime voiding; 5. Urinary urgency; 6. Taking a long time to urinate; 7. Need abdominal pressure to void; 8. Dribbling, leakage, and/or accidents. Each urinary symptom in the DRAQ will be evaluated by a participant using the PGI-I (discrete variables with seven categories) at the end of each treatment period, compared with how the symptom was before the participant's began taking medication in this study. The percentage of participants who reported a PGI-I (Drug Attributes Questionnaire) score of 1 to 3 are presented in the table below.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With PGI-I (Drug Attributes Questionnaire) on 8 Symptoms for BPH-Lower Urinary Tract Symptoms Improvement
percentage of participantsTadalafilPlacebo
Difficulty to void -44.937.9
Frequent nighttime voiding48.542.9
Feeling of incomplete emptying48.534.8
Frequent daytime voiding42.537.9
Urinary urgency37.131.7
Taking a long time to urinate42.532.9
Need abdominal pressure to void33.533.5
Dribbling, leakage, and/or accidents26.927.3

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil—0/167 (0%)47/167 (28.1%)
Placebo—0/161 (0%)39/161 (24.2%)
Most frequent other events
Showing 10 of 62
Most frequent other events
EventTadalafilPlacebo
NasopharyngitisInfections and infestations13/16713/161
Blood creatine phosphokinase increasedInvestigations2/1674/161
Abdominal discomfortGastrointestinal disorders4/1670/161
VertigoEar and labyrinth disorders3/1670/161
Back painMusculoskeletal and connective tissue disorders3/1671/161
ConstipationGastrointestinal disorders0/1672/161
DyspepsiaGastrointestinal disorders2/1670/161
HeadacheNervous system disorders2/1670/161
ProstatitisReproductive system and breast disorders2/1670/161
AnaemiaBlood and lymphatic system disorders0/1671/161

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Tadalafil/PlaceboPlacebo/TadalafilTotal
Mean61.4 ± 6.262.0 ± 5.861.7 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)Tadalafil/PlaceboPlacebo/TadalafilTotal
Female000
Male8586171
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tadalafil/PlaceboPlacebo/TadalafilTotal
Hispanic or Latino000
Not Hispanic or Latino8586171
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tadalafil/PlaceboPlacebo/TadalafilTotal
American Indian or Alaska Native000
Asian8586171
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Tadalafil/PlaceboPlacebo/TadalafilTotal
Japan8586171
Current Smoking Habit
Current Smoking Habit(participants)Tadalafil/PlaceboPlacebo/TadalafilTotal
Yes142034
No7166137
08

Study locations

9 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 604-8436, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Maebashi, 371-0805, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 542-0073, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sagamihara, 252-0303, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sakai, 590-0024, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suita, 565-0874, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Takasaki, 370-0826, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Takatsuki, 569-1115, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 132-0011, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2015
First posted
May 1, 2015
Start
Apr 2015
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Mar 1, 2017
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02431754
Collaborators
Nippon Shinyaku Co., Ltd.
Responsible party
Sponsor
First posted
May 1, 2015
Start date
Apr 2015
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Mar 1, 2017
Last update
Jul 2, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion